---
figid: PMC5507649__onco12152-fig-0002
figlink: /pmc/articles/PMC5507649/figure/onco12152-fig-0002/
number: Figure 2
caption: 'Targeting the ALK signaling pathway. (A): Upon ligand binding, dimerization
  of wild‐type ALK leads to kinase activation and phosphorylation. ALK activation
  results in the initiation of a number of signaling cascades involved in promoting
  cell proliferation and survival. (B): Unlike wild‐type ALK, the STRN‐ALK fusion
  protein is constitutively dimerized and activated allowing for hyperactivation of
  downstream signaling pathways and oncogenic growth. Emerging clinical and preclinical
  data indicates that the STRN‐ALK fusion protein may be sensitive to ALK inhibitors,
  such as crizotinib or ceritinib; therefore, ALK inhibitors may be a potential therapeutic
  strategy for patients with these alterations.'
pmcid: PMC5507649
papertitle: Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based
  Assay of Circulating Tumor DNA.
reftext: Andrea Z. Lai, et al. Oncologist. 2017 Jul;22(7):774-779.
pmc_ranked_result_index: '82959'
pathway_score: 0.9063673
filename: onco12152-fig-0002.jpg
figtitle: Targeting the ALK signaling pathway
year: '2017'
organisms: Homo sapiens
ndex: f3ca33bd-dea0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5507649__onco12152-fig-0002.html
  '@type': Dataset
  description: 'Targeting the ALK signaling pathway. (A): Upon ligand binding, dimerization
    of wild‐type ALK leads to kinase activation and phosphorylation. ALK activation
    results in the initiation of a number of signaling cascades involved in promoting
    cell proliferation and survival. (B): Unlike wild‐type ALK, the STRN‐ALK fusion
    protein is constitutively dimerized and activated allowing for hyperactivation
    of downstream signaling pathways and oncogenic growth. Emerging clinical and preclinical
    data indicates that the STRN‐ALK fusion protein may be sensitive to ALK inhibitors,
    such as crizotinib or ceritinib; therefore, ALK inhibitors may be a potential
    therapeutic strategy for patients with these alterations.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NRAS
  - ARAF
  - HRAS
  - KRAS
  - AKT2
  - MAP2K1
  - RAF1
  - AKT1
  - MAPK3
  - PTN
  - STAT3
  - BRAF
  - PIK3R3
  - PIK3R5
  - PIK3CG
  - ALK
  - MAPK1
  - PIK3CD
  - PIK3CA
  - MAP2K2
  - PIK3R6
  - STRN
  - PIK3R4
  - AKT3
  - PIK3CB
  - Phosphate
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: (PTN,
  symbol: PTN
  source: hgnc_symbol
  hgnc_symbol: PTN
  entrez: '5764'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: ALK
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: STRN
  symbol: STRN
  source: hgnc_symbol
  hgnc_symbol: STRN
  entrez: '6801'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
chemicals:
- word: Phosphate
  source: MESH
  identifier: D010710
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
